(Q54678404)

2 June 2018

title

Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos. (English)

1 reference

2 June 2018

1 reference

1 reference

Mehmet Bayram

1

1 reference

2 June 2018

Isa Dongel

2

1 reference

2 June 2018

Ali Akbaş

3

1 reference

2 June 2018

Ismail Benli

4

1 reference

2 June 2018

Muhammed Emin Akkoyunlu

5

1 reference

2 June 2018

Nur Dilek Bakan

6

1 reference

2 June 2018

publication date

30 October 2013

1 reference

2 June 2018

published in

Lung

1 reference

2 June 2018

volume

192

1 reference

2 June 2018

issue

1

1 reference

2 June 2018

page(s)

197-203

1 reference

2 June 2018

https://scigraph.springernature.com/pub.10.1007/s00408-013-9526-9

exact match

0 references

cites work

Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9526-9

Epidemiology, biologic behavior, and natural history of mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9526-9

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9526-9

Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9526-9

Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9526-9

MESOMARK: a potential test for malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9526-9

Osteopontin levels in an asbestos-exposed population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9526-9

Asbestos-related pleural disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9526-9

High risk of malignant mesothelioma and pleural plaques in subjects born close to ophiolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9526-9

Pleural mesothelioma in New Caledonia: associations with environmental risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9526-9

Increased risk of malignant mesothelioma of the pleura after residential or domestic exposure to asbestos: a case-control study in Casale Monferrato, Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9526-9

Residential proximity to naturally occurring asbestos and mesothelioma risk in California

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9526-9

Environmental asbestos exposure and mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9526-9

Applying definitions of "asbestos" to environmental and "low-dose" exposure levels and health effects, particularly malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9526-9

Is living close to ophiolites related to asbestos related diseases? Cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9526-9

Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9526-9

Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9526-9

Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9526-9

Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9526-9

Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9526-9

Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9526-9

Glomerular filtration rate is a confounder for the measurement of soluble mesothelin in serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9526-9

Osteopontin is increased in the bronchoalveolar lavage fluid and bronchial tissue of smoking asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9526-9

Mesothelin-family proteins and diagnosis of mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9526-9

Combined CA125 and Mesothelin Levels for the Diagnosis of Malignant Mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9526-9

Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9526-9

Soluble Mesothelin–related Peptides in the Diagnosis of Malignant Pleural Mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9526-9

Assessment of environmental asbestos exposure in Turkey by bronchoalveolar lavage

21 January 2018

1 reference

12 December 2020

Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer.

1 reference

12 December 2020

An epidemiological study in an Anatolian village environmentally exposed to tremolite asbestos

1 reference

12 December 2020

Asbestos exposure, pleural mesothelioma, and serum osteopontin levels

1 reference

12 December 2020

Mesothelioma in Cyprus

1 reference

12 December 2020

Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma

1 reference

12 December 2020

The assessment of the malignant mesothelioma cases and environmental asbestos exposure in Sivas province, Turkey

1 reference

12 December 2020

Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best?

1 reference

12 December 2020

Decreasing prevalence of pleural calcifications among Metsovites with nonoccupational asbestos exposure

1 reference

12 December 2020

[Environmental mesotheliomas in northeast Corsica]

1 reference

12 December 2020

Latency periods in asbestos-related mesothelioma of the pleura

1 reference

12 December 2020

The continual search for ideal biomarkers for mesothelioma: the hurdles.

1 reference

12 December 2020

Impact of renal failure on the tumor markers of mesothelioma, N-ERC/mesothelin and osteopontin

1 reference

12 December 2020

10.1007/S00408-013-9526-9

Identifiers

DOI

1 reference

2 June 2018

1 reference

2 June 2018